Rose is an associate editorial director at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
MRD Kinetics Identify High-risk CLL in Study of Zanubrutinib, Venetoclax, Obinutuzumab
January 16th 2022An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration.
Increased Patient-Physician Dialogue in EDs May Reduce Polypharmacy in Older Patients
January 8th 2022A Danish study observed emergency department (ED) health care providers and identified 5 factors that could play into patient involvement in medication discussions, particularly in older patients with polypharmacy.
Could GLP-1 RAs Improve COVID-19-Induced Pulmonary Arterial Hypertension?
December 30th 2021Recent studies show that glucagon-like peptide-1 receptor agonists have anti-inflammatory effects in human and rodent pathological models, making them a potential therapeutic strategy for treating pulmonary arterial hypertension after COVID-19 infection.
Pediatric Patients With ASMD Show Significant Improvement in Olipudase Alfa Trial
December 4th 2021Findings from the single-arm, open-label ASCEND-Peds trial suggest olipudase alfa is well-tolerated and may lead to clinically meaningful improvements in patients with acid sphingomyelinase deficiency (ASMD) who do not have neurovisceral manifestations.
Pilot Program Underscores Importance of Newborn Screening to Identify, Treat SMA
December 2nd 2021Testing for spinal muscular atrophy in an Australian newborn screening program identified patients across socioeconomic and cultural demographics, mitigating inequity and providing patients with access to multidisciplinary treatment.
Uveitic Macular Edema Increases Costs Among Patients With Noninfectious Uveitis
November 12th 2021Uveitic macular edema is common in patients with noninfectious uveitis, and its significant burden on patients and payers warrants more specific treatment guidelines to minimize quality-of-life and economic effects.
Analysis of Nusinersen Shows Favorable Safety Profile in Adults With SMA
November 11th 2021Data on nusinersen’s safety profile in adult patients are more limited than in infant and adolescent patients, but a recent study showed positive results based on cerebrospinal fluid and blood sample parameters.
Nonadherence to Nusinersen Treatment Increases Health Care Utilization, Costs in SMA
November 5th 2021Results of a retrospective claims database analysis suggest that adherence to scheduled intrathecal nusinersen injections may lead to improvements in comorbidities, health care utilization, and costs for spinal muscular atrophy (SMA) types 1, 2, and 3.
Case Study Suggests Further Research on Benign Focal Hepatic Lesions in ASMD
November 5th 2021Imaging studies and subsequent biopsies of a liver lesion showed a foamy macrophages aggregate in a 30-year-old patient with acid sphingomyelinase deficiency (ASMD) similar to those found in Gaucher disease.